María Elena Barrios, CEO & FOUNDER.
Administrator. Currently graduating in Degree in Sociology and Labor Relations from the Pablo de Olavide University. More than 15 years of experience in business management in the field of biotechnology and human health. Competence in the management of companies.
Dr. José Antonio Horcajadas Almansa, SCIENTIFIC DIRECTOR (CSO) & FOUNDER.
PhD in Molecular Biology and Biochemistry from the Autonomous University of Madrid. He has a solid experience in the field of Genetics of Human Reproduction, especially in the area of endometrial receptivity, genomics, transcriptomics, implantation and embryonic viability. He has been Laboratory Director of the IVI Foundation for the period 2002-2009 and Scientific Director of iGenomix in 2009-2011. Currently as CSO of Recombine Europe.
He has published more than 50 scientific papers and a patent, more than 10 books and book chapters, and has given more than 80 lectures in the last 5 years. In addition to his scientific training, he is Professor of Genetics at the Pablo de Olavide University in Seville, Associate Professor at the Eastern Virginia Medical School in Norfolk, Virginia, USA and Professor at the University of La Plata, La Plata, Argentina.
Dr. David Cotán Marín, TECHNICAL DIRECTOR (CTO).
Doctor of Biotechnology and Bachelor of Environmental Science from Pablo de Olavide University (Seville). Entrepreneur, specialized in technical management and project management in the field of rare diseases, reproduction and scaling of enzymes in the Andalusian Center for Developmental Biology. The research group works on different lines of research on cell death, human reproduction and rare diseases. Professor at the University of La Plata, La Plata, Argentina.
Antonio Martínez, EXTERNAL SCIENTIFIC ADVISOR.
Degree in Biology from the University of Seville, Master in Biotechnology from the Universidad Pablo de Olavide. Training in Creation, Consolidation of companies and Development of new business models. Expert in international operations. Responsible for the line of autoimmune diseases and commercial action.